Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis

Leukemia & Lymphoma
J DrachM Andreeff

Abstract

Expression of MDR1 is a well-characterized mechanism leading to resistance of tumor cells to drugs like vinca-alkaloids, anthracyclines, and epipodophyllotoxins. In hematopoiesis, recent data indicate that not only leukemic cells, but also some populations of normal hematopoietic cells, particularly CD34+ progenitor cells as well as peripheral blood lymphocytes, express a functional multidrug-resistant phenotype. Among CD34+ cells, we found evidence that myeloid committed precursor cells (CD34+/CD33+) have lower levels of MDR1 expression than earlier CD34+ cell populations, but there was no difference in MDR1 expression between CD34+/HLA-DR- and CD34+/HLA-DR+ subpopulations. During normal myeloid differentiation, MDR1 expression is down-regulated, which is similar to our observations in acute myelogenous leukemia (AML): MDR1 expression was only rarely detected in acute promyelocytic leukemia, which was in contrast to other subtypes of AML; also, within leukemic subpopulations of the same patient, higher MDR1 levels were correlated with a more immature immunophenotype. Regarding regulation of MDR1 expression, we did not observe changes of MDR1 expression in normal CD34+ cells in response to various cytokines. However, in 2 patie...Continue Reading

References

Jun 1, 1992·British Journal of Haematology·J P MarieB I Sikic
Sep 1, 1992·British Journal of Haematology·C LudescherJ Hofmann
Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M YahandaB I Sikic
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T P MillerS E Salmon
May 15, 1991·Journal of the National Cancer Institute·R PirkerL Havelec
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W S DaltonS E Salmon
Mar 2, 1988·Journal of the National Cancer Institute·J A Moscow, K H Cowan
May 28, 1987·The New England Journal of Medicine·I Pastan, M Gottesman
Jan 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A L ChengC H Wang
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A F ListW Dalton

❮ Previous
Next ❯

Citations

Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M BaudardM M Gottesman
Mar 18, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Tsukasa HayashiYuzuru Takemura
Jul 1, 2003·Clinical and Applied Immunology Reviews·Shona S PendseMarkus H Frank
Jun 1, 1995·British Journal of Haematology·D DrachM Andreeff
Nov 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lujia DongDao-Pei Lu
Oct 11, 2005·Critical Reviews in Oncology/hematology·Wolfgang KernSusanne Schnittger
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M H FrankD M Briscoe
Aug 19, 2014·The Journal of Clinical Investigation·Gina M AloisioDiego H Castrillon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.